TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8026054

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (250,000 U in divided doses)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase (500,000 U in divided doses)
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Intracoronary urokinase
Number of subjects: 469

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study: 2740970

Group type: EXPERIMENTAL
Intervention: Cervical anastomosis (CA)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Thoracic anastomosis (TA)
Number of subjects: 92
Study: 4138966

Group type: COMPARATOR
Intervention: CCNU (130 mg/m2 orally every 6 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 5 azacytidine (60 mg/m2 intravenously daily for 10 days and twice weekly thereafter)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (two dose schedules)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Immunologic skin testing
Number of subjects: 58
Study: 29877722

Group type: EXPERIMENTAL
Intervention: Cow milk-based nutrition (0% to 100%)
Number of subjects: 260
Study: 28605740

Group type: EXPERIMENTAL
Intervention: Famotidine with acotiamide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo with acotiamide
Number of subjects: 50
Study: 26154454

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) application (6J)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 79
Study: 23454058

Group type: EXPERIMENTAL
Intervention: Boceprevir (400 mg TID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21673013

Group type: EXPERIMENTAL
Intervention: Myofascial release techniques
Number of subjects: 86

Group type: COMPARATOR
Intervention: Sham short‐wave and ultrasound electrotherapy
Number of subjects: 86
Study: 18434021

Group type: EXPERIMENTAL
Intervention: Kangaroo method (skin-to-skin contact)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Oral glucose (1 ml, 25%)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Isolette (no analgesia)
Number of subjects: 95
Study: 16868824

Group type: EXPERIMENTAL
Intervention: Carmint plus Loperamide or Psyllium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo plus Loperamide or Psyllium
Number of subjects: 32
Study: 12971247

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel agents and/or combination therapies
Number of subjects: 0
Study: 10233189

Group type: EXPERIMENTAL
Intervention: RBC400OM: RBC 400 mg b.d., oxytetracycline 500 mg q.d.s.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RBC400SM: RBC 400 mg b.d., spiramycin 1 g q.d.s.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RBC200OM: RBC 200 mg q.d.s., oxytetracycline 500 mg q.d.s.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: RBC200SM: RBC 200 mg q.d.s., spiramycin 1 g q.d.s.
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ulcer patients
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Non-ulcer patients
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Never smoked
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 183
Study: 9119918

Group type: EXPERIMENTAL
Intervention: Risperidone 4-16 mg/day
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Haloperidol 10-20 mg/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 7
Study: 2119562

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 25

Group type: COMPARATOR
Intervention: No Mannitol
Number of subjects: 25
Study: 7407606

Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 31230881

Group type: EXPERIMENTAL
Intervention: Low dose formulation of the EV71 vaccine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High dose formulation of the EV71 vaccine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study: 27710006

Group type: EXPERIMENTAL
Intervention: Strong Families Strong Forces Parenting Program
Number of subjects: 115

Group type: COMPARATOR
Intervention: Waitlist comparison group
Number of subjects: 115
Study: 25556770

Group type: EXPERIMENTAL
Intervention: Intervention schools with new meal pattern (students could select one fruit and two vegetable servings per reimbursable meal)
Number of subjects: 1576

Group type: COMPARATOR
Intervention: Control schools with previous meal pattern (students could select a total of two fruit and vegetable servings per meal)
Number of subjects: 1576
Study: 24462850

Group type: EXPERIMENTAL
Intervention: LigaSure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HALO PKS cutting forceps
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ENSEAL tissue sealer
Number of subjects: 45
Study: 23116189

Group type: EXPERIMENTAL
Intervention: Dil Mil intervention plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 20229041

Group type: EXPERIMENTAL
Intervention: Intravenous injection of E. coli lipopolysaccharide (LPS) at a dosage of 0.3 ng/kg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous injection of E. coli lipopolysaccharide (LPS)
Number of subjects: 42
Study: 17504848

Group type: EXPERIMENTAL
Intervention: Cataract surgery with combined primary posterior capsulorhexis (PPC) and posterior optic buttonholing (POBH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional in‐the‐bag IOL implantation
Number of subjects: 50
Study: 16326367

Group type: EXPERIMENTAL
Intervention: Environmental and behavioral interventions (EBI) during weighing procedures
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (without EBI) during weighing procedures
Number of subjects: 45
Study: 12053830

Group type: EXPERIMENTAL
Intervention: Physiotherapy for multiple sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapy for Parkinson's disease
Number of subjects: 0
Study: 10463897

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 8778004

Group type: EXPERIMENTAL
Intervention: Self placental antigens (SPA) reactivity assessed by leucocyte‐migration inhibition assay
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Anti-fetal lymphocyte cytotoxic antibodies (AFCA) detection using complement dependent microcytotoxicity assay
Number of subjects: 27
Study: 3149202

Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg intravenous bolus followed by 2.5 mg/h continuous infusion)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29562853

Group type: EXPERIMENTAL
Intervention: Virtual cognitive remediation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 51
Study: 31634738

Group type: EXPERIMENTAL
Intervention: Stepped care (internet CBT with telephone support)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 270

Group type: COMPARATOR
Intervention: tCBT
Number of subjects: 270
Study: 28877913

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 5529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5529
Study: 26582116

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise using electric stimulation and biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self pelvic floor muscle exercise
Number of subjects: 30
Study: 23782962

Group type: EXPERIMENTAL
Intervention: Flu-50 (0.5 ml)
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Flu-25 (0.25 ml)
Number of subjects: 3320

Group type: COMPARATOR
Intervention: Control vaccine (Fluzone®; 0.25 ml)
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Flu-25
Number of subjects: 3320

Group type: EXPERIMENTAL
Intervention: Flu-50
Number of subjects: 3320

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3320
Study: 21186077

Group type: EXPERIMENTAL
Intervention: NSS (Nephron‐sparing surgery)
Number of subjects: 541

Group type: COMPARATOR
Intervention: RN (Radical nephrectomy)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: NSS
Number of subjects: 541

Group type: COMPARATOR
Intervention: RN
Number of subjects: 541
Study: 18695440

Group type: EXPERIMENTAL
Intervention: Eptifibatide and unfractionated heparin according to the ESPRIT protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and unfractionated heparin
Number of subjects: 0
Study: 20409103

Group type: EXPERIMENTAL
Intervention: Kangaroo care, peer counseling, in-home breast milk intake measurement, and postdischarge lactation support
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Postdischarge interventions
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Pre- and postdischarge interventions
Number of subjects: 310
Study: 16109110

Group type: EXPERIMENTAL
Intervention: Acetaminophen (500 mg), Aspirin (500 mg), Caffeine (130 mg)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Sumatriptan (50 mg)
Number of subjects: 171
Study: 12097446

Group type: EXPERIMENTAL
Intervention: elmex fluid (10,000 ppm F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 9495394

Group type: EXPERIMENTAL
Intervention: Positive inotropic drugs (PIDs) including amrinone, dobutamine, epinephrine, or dopamine (≥ 5 microg x kg[‐1] x min[‐1])
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Positive inotropic drugs (PIDs)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (no PIDs)
Number of subjects: 149
Study: 7809347

Group type: EXPERIMENTAL
Intervention: Health Complaints Scale (HCS) in 60 subjects participating in cardiac rehabilitation
Number of subjects: 535

Group type: COMPARATOR
Intervention: Health Complaints Scale (HCS) in 60 control subjects
Number of subjects: 535
Study: 3044007

Group type: EXPERIMENTAL
Intervention: Maprotiline 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amitriptyline 50 mg
Number of subjects: 12
Study: 11250628

Group type: EXPERIMENTAL
Intervention: Antisialagogue (glycopyrrolate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30606262

Group type: EXPERIMENTAL
Intervention: Evidence Project risk of bias tool
Number of subjects: 125
Study: 30019500

Group type: EXPERIMENTAL
Intervention: 4-7 alcohol units per week
Number of subjects: 323

Group type: COMPARATOR
Intervention: <1-3 alcohol units per week
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: ≥8 alcohol units per week
Number of subjects: 323
Study: 27089361

Group type: COMPARATOR
Intervention: Water and walk (WW)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose and walk (GW)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose (G)
Number of subjects: 29
Study: 24559015

Group type: EXPERIMENTAL
Intervention: 200 mL of an oral nutritional supplement containing maltodextrine and whey protein, consumed 150 to 210 min before gastroscopy
Number of subjects: 24

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 24
Study: 23098412

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg three times daily before and during ascent to 4928 m
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 21070615

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (17 standard points with 'de qi' manipulation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture (17 sham points of shallow penetration without manipulation)
Number of subjects: 42
Study: 17986746

Group type: EXPERIMENTAL
Intervention: RBC‐AT (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Tetracycline 500 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: RBC‐AC (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: RBC‐MT (Ranitidine Bismuth Citrate 400 mg, Metronidazole 500 mg, Tetracycline 500 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 300
Study: 15295374

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 140
Study: 11260412

Group type: EXPERIMENTAL
Intervention: Cyclosporine plus low-dose prednisone
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9678816

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate (300 mg q.d.s.), omeprazole (20 mg b.d.), and amoxycillin (500 mg q.d.s.) for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omeprazole (20 mg b.d.) and amoxycillin (500 mg q.d.s.) for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bismuth subnitrate with dual oral therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dual oral therapy alone
Number of subjects: 50
Study: 8305276

Group type: EXPERIMENTAL
Intervention: Barium sulfate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonionic low-osmolar contrast medium
Number of subjects: 36
Study: 2972802

Group type: EXPERIMENTAL
Intervention: Cue tone or chord heard by subjects to form an image of a tone or chord one whole step in pitch above the cue.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random-tone mask used in Experiment 3 to control for echoic memory.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagery instructions provided in Experiments 1 and 3.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Predictions made by subjects in Experiment 2 regarding 'an average person' using imagery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task completed without imagery instructions in Experiment 4.
Number of subjects: 0
Study: 31837559

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (OD) for 6 months, started on day 3 postoperatively
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg OD
Number of subjects: 10
Study: 29282633

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1326

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Ertugliflozin
Number of subjects: 1326

Group type: EXPERIMENTAL
Intervention: Ertugliflozin and Glimepiride
Number of subjects: 1326
Study: 28240608

Group type: EXPERIMENTAL
Intervention: demineralized bone matrix + collagen membrane (CM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: hydroxyapatite bone substitute (HBS) + CM
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 17

Group type: COMPARATOR
Intervention: left empty
Number of subjects: 17
Study: 26149987

Group type: EXPERIMENTAL
Intervention: SUBA-itraconazole
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sporanox
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 7
Study: 24130350

Group type: EXPERIMENTAL
Intervention: HCLC followed by SAP therapy (intensive group; N = 48)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual-care group treated with multiple daily injections or insulin pump therapy (N = 20)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HCLC followed by SAP therapy (intensive group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 68
Study: 20955776

Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg twice a day for 5 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18300967

Group type: EXPERIMENTAL
Intervention: Incisional wounds
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Excisional wounds
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Anteriorly placed incisional scars
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Posteriorly placed excisional scars
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All scars
Number of subjects: 103
Study: 16781295

Group type: EXPERIMENTAL
Intervention: Finasteride (1 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12622663

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nucleus (STIM ON)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levodopa (MED)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Deep brain stimulation off (STIM OFF)
Number of subjects: 12
Study: 10230169

Group type: EXPERIMENTAL
Intervention: Caffeinated soft drink (CC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mineral water (MW)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Urine color, osmolality and SEC
Number of subjects: 8
Study: 8916812

Group type: EXPERIMENTAL
Intervention: Z‐BUF (high-volume, zero‐fluid balance ultrafiltration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 1884747

Group type: EXPERIMENTAL
Intervention: Rythmodan L.A. 250 mg b.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dirytmin Durettes 300 mg b.d.
Number of subjects: 10
Study: 6819898

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of metoclopramide and lisuride
Number of subjects: 24
Study: 30863044

Group type: EXPERIMENTAL
Intervention: Claims-based predictive model (likely to have undiagnosed COPD)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Claims-based predictive model (not likely to have undiagnosed COPD)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Predictive model performance metrics
Number of subjects: 549
Study: 29053808

Group type: EXPERIMENTAL
Intervention: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso‐zeaxanthin; n = 60
Number of subjects: 121

Group type: COMPARATOR
Intervention: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 27113126

Group type: EXPERIMENTAL
Intervention: Fastrach/pillowless
Number of subjects: 193

Group type: COMPARATOR
Intervention: air-Q/pillowless
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Fastrach/head-elevated
Number of subjects: 193

Group type: COMPARATOR
Intervention: air-Q/head-elevated
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: head-elevated position
Number of subjects: 193
Study: 24063909

Group type: EXPERIMENTAL
Intervention: Sodium butyrate with short-chain fatty acids
Number of subjects: 42
Study: 22889693

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Strength exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study: 19317825

Group type: EXPERIMENTAL
Intervention: Physical activity consultation delivered by a person
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Physical activity consultation delivered in written form
Number of subjects: 134

Group type: COMPARATOR
Intervention: All groups (including both interventions and control)
Number of subjects: 134
Study: 17582652

Group type: EXPERIMENTAL
Intervention: Patient education prior to discharge
Number of subjects: 588

Group type: COMPARATOR
Intervention: Non-educated group
Number of subjects: 588
Study: 14747781

Group type: EXPERIMENTAL
Intervention: DMPA (injectable hormonal contraceptive)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (no contraceptive steroid)
Number of subjects: 140
Study: 12659397

Group type: EXPERIMENTAL
Intervention: NuvaRing (15 microgram ethinylestradiol and 120 microgram etonogestrel per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NuvaRing (3 days of use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed ring insertion (when follicles had developed to 13 mm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined oral contraceptive (30 microgram ethinylestradiol and 150 microgram desogestrel)
Number of subjects: 0
Study: 10910608

Group type: EXPERIMENTAL
Intervention: Local manipulation (massage and hot packing) after vaccinations
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Local manipulation (massage and hot packing) after DTPa vaccinations for two minutes
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group (only vaccinations without manipulation)
Number of subjects: 808
Study: 7472661

Group type: EXPERIMENTAL
Intervention: Low nitrogen and low calcium diet (0.49 +/- 0.11 g protein/(kg.d), 429 +/- 190 mg calcium/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low nitrogen and high calcium diet (0.44 +/- 0.08 g protein/(kg.d), 1643 +/- 171 mg calcium/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High nitrogen and high calcium diet (2.71 +/- 0.75 g protein/(kg.d), 1589 +/- 633 mg calcium/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline dietary intake (0.99 +/- 0.51 g protein/(kg.d), 589 +/- 152 mg calcium/d)
Number of subjects: 15
Study: 2137497

Group type: EXPERIMENTAL
Intervention: Method 1 (specific method not detailed)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypothermia blanket
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Method 2 (specific method not detailed)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Method 3 (specific method not detailed)
Number of subjects: 21
Study: 6791396

Group type: EXPERIMENTAL
Intervention: Sublingual administration of 1.6 mg of nitroglycerin (Group I)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (Group II)
Number of subjects: 17
Study: 30200089

Group type: EXPERIMENTAL
Intervention: UEScope videolaryngoscope
Number of subjects: 85

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 85